Eiger BioPharmaceuticals, Inc. announced the completion of enrollment of LOWR HDV 3 at the National Institutes of Health Clinical Center in Bethesda, Maryland. LOWR HDV 3 is a double-blinded, randomized, placebo-controlled study designed to evaluate the efficacy and tolerability of three doses of lonafarnib " 50 mg, 75 mg and 100 mg " once daily, each combined with ritonavir 100 mg once daily. Twenty-one people with chronic hepatitis delta will be placed in one of six treatment groups.

Each group will receive different doses of the study drugs for 12 or 24 weeks. Enrollment was completed in less than 4 months.